Dr Markus Laubach | Biomaterials | Best Researcher Award

Dr Markus Laubach | Biomaterials | Best Researcher Award

Dr Markus Laubach, LMU University Hospital Munich, Germany

Dr. Markus Laubach 🎓🩺 is a distinguished researcher in orthopaedics and medical innovation. Holding a Ph.D. in preclinical assessment of novel medical devices, an MBA in Healthcare Management, and certifications in emergency medicine, he combines clinical expertise with research excellence. 🏥🔬 His groundbreaking work focuses on scaffold-guided bone regeneration, 3D-printed implants, and bone grafting techniques, published in top journals like Biomaterials Science and Scientific Reports. 💡📚 Dr. Laubach has secured over EUR 350,000 in grants and won prestigious awards, including the Best Poster Award at DKOU 2023. 🌍 He actively collaborates globally, advancing orthopaedic trauma care. 🦴✨

Publication Profile

Orcid

Scopus

Education and Training🎓

Dr. Markus Laubach 🎓 began his educational journey at Stefan-George-Gymnasium, earning his Abitur in 2007 🎒. He trained as a paramedic 🚑 at Arbeiter-Samariter-Bund in 2008. He pursued Medicine 🩺 at Maastricht University (2010–2016) and earned his Dr. med. from Charité Berlin in 2019 📚, focusing on brain aging and executive functioning 🧠. Further, he specialized in Emergency Medicine 🚨 and completed his Ph.D. at QUT 🦴 (2020–2023), researching bone graft aspirator devices. Recently, he earned an MBA 🎓 in Health Care Management 🏥. Currently, he advances orthopaedic research at LMU Munich through the prestigious Feodor Lynen Fellowship 🌍.

Professional Experience💼

Dr. Markus Laubach 🩺 has extensive professional experience in orthopaedics and trauma surgery. He is currently a Resident at the LMU University Hospital 🏥, Musculoskeletal University Center Munich (2023–present). Previously, he worked as a Resident at RWTH Aachen University Hospital (2016–2020) 🦴, advancing his surgical expertise. Dr. Laubach further honed his skills in medtech commercialization through The BridgeTech Program 🌐 in Australia (2021–2022). His medical journey began as a Paramedic 🚑 with organizations like Malteser Hilfsdienst (2011–2016), Arbeiter Samariter Bund (2009–2010), and DRK Rettungsdienst GmbH (2008–2009), reflecting his dedication to emergency medical care and patient well-being 🤝.

Research Focus Area 🌱🧬

Markus Laubach is a researcher specializing in biomaterials, bone regeneration, and spinal surgery innovations. His work primarily focuses on advancing implants, scaffolds, and bone grafts for clinical applications, particularly in lumbar spinal fusion and bone defect treatments. He is involved in designing 3D printable, patient-specific bioresorbable bone scaffolds to promote bone regeneration. Laubach’s research extends to the development of novel bone graft harvesting techniques and the assessment of biodegradable interbody cages. His work intersects with orthopaedic trauma, regenerative medicine, and biomechanics. 🦴🧬🩺

Memberships

Dr. Markus Laubach is an active member of several prestigious medical and research organizations. He is affiliated with AO Trauma 🦵, focusing on advancing trauma care, and the Deutsche Gesellschaft für Orthopädie und Unfallchirurgie (DGOU) 🇩🇪, which promotes orthopedic and trauma surgery excellence. He also participates in the Gesellschaft für Extremitätenverlängerung und -rekonstruktion (GEVR) 🦴, dedicated to extremity reconstruction. Additionally, Dr. Laubach is a member of the Orthopaedic Research Society (ORS) 🔬 and the Tissue Engineering and Regenerative Medicine International Society (TERMIS) 🌍, contributing to cutting-edge research in tissue engineering and regenerative medicine.

Awards🏆

Dr. Markus Laubach has received notable recognition for his scientific contributions. In 2023, he was awarded the Best Poster Award at the DKOU 2023 in Berlin 🏆. His research has attracted competitive grants, including EUR 182,022.36 from the Bundesministerium für Bildung und Forschung for a clinical study on tibial transverse callus distraction in diabetic foot ulcer patients 💉, and EUR 39,600 from the Feodor Lynen Return Fellowship 🏅. Dr. Laubach also secured funding from the Volkswagen Foundation (EUR 38,000) and Clive & Vera Ramaciotti Foundation (AUD 130,000) for innovative bone defect treatments using 3D-printed scaffolds.

Publication Top Notes📄✨

Advances in implants and bone graft types for lumbar spinal fusion surgery

Modular design workflow for 3D printable bioresorbable patient-specific bone scaffolds: extended features and clinical validation.

Preclinical assessment of a novel aspirator device for intramedullary bone graft harvesting

Lost in translation: the lack of agreement between surgeons and scientists regarding biomaterials research and innovation for treating bone defects

An innovative intramedullary bone graft harvesting concept as a fundamental component of scaffold-guided bone regeneration: A preclinical in vivo validation

Chirurg*innen vs. Wissenschaftler*innen – Mind the Gap! DKOU Science-Slam 2023: Umfragestudie zu Biomaterialien bei Knochendefekten [Surgeons vs. scientists—Mind the gap!: Survey study on biomaterials for bone defects]

How framing bias impacts preferences for innovation in bone tissue engineering

Semi-automated scaffold design workflow to facilitate clinical translation of scaffold guided bone regeneration

The development of a modular design workflow for 3D printable bioresorbable patient-specific bone scaffolds to facilitate clinical translation

Histological and Immunohistochemical Characterization of Osteoimmunological Processes in Scaffold-Guided Bone Regeneration in an Ovine Large Segmental Defect Model

Conclusion

Dr. Markus Laubach’s robust academic foundation, exceptional research achievements, successful funding track record, and dedication to clinical translation make him an excellent candidate for the Best Researcher Award. His work directly addresses critical gaps in bone defect treatments, contributing both to scientific innovation and practical healthcare advancements.

Dalia Zaafar | Biomaterials | Women Researcher Award

Dalia Zaafar | Biomaterials | Women Researcher Award

Assist. Prof. Dr Dalia Zaafar, Cairo University, Egypt

Dr. Dalia Zaafar is an Assistant Professor at Modern University for Technology and Information (MTI) in Egypt, specializing in pharmacology, toxicology, and clinical pharmacy. With a Ph.D. from Cairo University, she has led impactful research on cardiovascular pharmacology and oncology. 🌍 Her work includes clinical studies, focusing on metformin and sorafenib, contributing to drug safety. Dr. Zaafar is passionate about mentoring young researchers, especially women in academia, and has presented at international conferences. 🎓 She holds certifications in clinical practice and data analysis, enhancing her role as an expert in her field. 📚

Publication Profile

Google Scholar

Orcid

Scopus

Educational Background 🎓

Dr. Dalia Zaafar holds a Ph.D. in Pharmacology and Toxicology from Cairo University (2019), with a focus on clinical studies and cardiovascular pharmacology. Her dissertation explored the efficacy and safety of dipeptidyl peptidase inhibitors versus Metformin in diabetic hypertensive patients. 🎓 She earned an M.A. in Pharmacology and Toxicology from Suez Canal University (2014), specializing in oncology and endocrinology. Dr. Zaafar also completed a Clinical Pharmacy diploma (2019-2021) in critical care and further honed her skills through a Data Analysis Professional Nano-degree (2021) and other specialized certifications in clinical pharmacology and pharmacoeconomics. 📚💻

Current Role and Focus 💼

Dr. Dalia Zaafar is an Assistant Professor at the Modern University for Technology and Information (MTI), Egypt, where she has been teaching and conducting research since 2019. 🌟 She designs experimental studies, collaborates internationally, and mentors young researchers. Additionally, she serves on the editorial boards of the Universal Journal of Pharmaceutical Research and the World Journal of Clinical Cases. 📘 Previously, she worked as a Clinical Pharmacist in critical care at Teacher’s Hospital and Abu Sower Medical Center. Dr. Zaafar has expertise in clinical pharmacy, research supervision, and interdisciplinary initiatives, fostering academic growth and innovation. 🧪👩‍🏫

Participation in Conferences 🌐

Dr. Dalia Zaafar was a speaker at the 18th International Conference of Biochemistry and Molecular Biology, held on September 16-17, 2023. 🌍 Her lecture, titled “Unravelling the Complexities of Tau Protein Dysfunction in Alzheimer’s Disease: Pathophysiology, Biomarkers, and Therapeutic Perspectives”, highlighted groundbreaking insights into the mechanisms of Alzheimer’s disease. 🧠🔬 She discussed emerging biomarkers and innovative therapeutic strategies, contributing to a deeper understanding of this critical neurodegenerative condition. Dr. Zaafar’s presentation underscored her expertise in molecular biology and her dedication to advancing research for a better future for humanity. 🌟

Research Focus Area 🌱🧬

Dr. Dalia Zaafar’s research is focused on pharmacology, toxicology, and clinical pharmacy, with a multidisciplinary approach to tackling critical health challenges. 🧪 Her studies emphasize drug safety, cardiovascular pharmacology, and oncology, exploring innovative therapeutic interventions for diseases like Alzheimer’s, Parkinson’s, colon cancer, and drug-induced toxicities. 🔬 Her work integrates molecular biology, nanotechnology, and experimental pharmacology, addressing mechanisms like tumor angiogenesis, neuroprotection, and signal pathway modulation. 🌍 Dr. Zaafar’s impactful contributions also span natural product-based therapies, nanoparticles for drug delivery, and biomarker development, making her a pioneer in advancing personalized medicine and enhancing treatment efficacy. 🌟

Publication Top Notes📚🌐

Role of metformin in suppressing 1, 2-dimethylhydrazine-induced colon cancer in diabetic and non-diabetic mice: effect on tumor angiogenesis and cell proliferation

Hesperetin mitigates sorafenib-induced cardiotoxicity in mice through inhibition of the TLR4/NLRP3 signaling pathway

Selenium nanoparticles with prodigiosin rescue hippocampal damage associated with epileptic seizures induced by pentylenetetrazole in rats

Orexin pathway in Parkinson’s disease: a review

Discovery of new 1, 3, 4-oxadiazoles with dual activity targeting the cholinergic pathway as effective anti-Alzheimer agents

Comparing the effectiveness of L-carnitine and paraffin oil in acute aluminum phosphide poisoning using predictive biomarkers and scores: a randomized controlled clinical trial

Adherence to insulin therapy among children with type 1 diabetes: reliability and validity of the Arabic Version of the 4-Item Morisky Medication Adherence Scale

Combined β-sitosterol and trimetazidine mitigate potassium dichromate-induced cardiotoxicity in rats through the interplay between NF-κB/AMPK/mTOR/TLR4 and HO-1/NADPH signaling …

Salix subserrata Bark ExtractLoaded Chitosan Nanoparticles Attenuate Neurotoxicity Induced by Sodium Arsenate in Rats in Relation with HPLC–PDA-ESI–MS …

Conclusion 🔍

Dr. Dalia Zaafar’s dedication to research excellence, her leadership in mentoring young women researchers, and her impressive body of scholarly work make her a highly suitable candidate for the Women Researcher Award. Her contributions to pharmacology, particularly in clinical studies, and her active role in global research collaborations position her as an influential figure in the academic community.